Press releases
- Novocure to Report Second Quarter 2024 Financial Results
- METIS Phase 3 Clinical Trial Met Primary Endpoint Significantly Delaying Time to Intracranial Progression with Improved Quality of Life Deterioration-Free Survival
- TIGER Study Reports New TTFields Therapy Survival Results for Newly Diagnosed Glioblastoma Patients in Germany
- Novocure Secures New $400 Million Multi-Tranche Non-Dilutive Debt Financing from Pharmakon
- Novocure Reports First Quarter 2024 Financial Results
- Results of Novocure’s METIS Phase 3 Clinical Trial for Patients with Brain Metastasis from Non-Small Cell Lung Cancer to be Presented as Late-Breaking Abstract at ASCO 2024
More ▼
Key statistics
On Monday, Novocure Ltd (N2VC34:SAO) closed at 10.53, 110.60% above the 52 week low of 5.00 set on Dec 01, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 10.53 |
---|---|
High | 10.53 |
Low | 10.53 |
Bid | 5.01 |
Offer | 15.00 |
Previous close | 10.53 |
Average volume | 176.25 |
---|---|
Shares outstanding | -- |
Free float | -- |
P/E (TTM) | -- |
Market cap | -- |
EPS (TTM) | -- |
Data delayed at least 15 minutes, as of Jul 22 2024 10:45 BST.
More ▼